Biotech has been one of the big winners of this aging bull market. Over the past 10 years, biotech stocks, on balance, have absolutely clobbered the broader U.S. stock markets. The reason is simple: innovation. Through the advent of game-changing molecular, cellular, and genetic technologies, biotech has been able to radically alter the standard of care for scores of hard-to-treat diseases.
The best part, though, is that the pace of innovation has actually been accelerating in recent years as the result of new sources of funding, novel partnerships that span one or more industries, as well as the emergence of several unique drug discovery and development platforms. Biotech, in kind, should remain a top wealth generator for years to come.
Image Source: Getty Images.